The REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) data requirements for mutagenicity and carcinogenicity have been compared to the criteria for classification under Classification, Labelling and Packaging (CLP) and the studies used as key evidence by Committee for Risk Assessment (RAC) in drafting its opinions on the appropriate classification. This comparison revealed that the REACH information requirements will not provide sufficient information to conclude a substance is a Cat 1B mutagen and/or carcinogen. In addition, requiring such information via a substance evaluation under REACH requires a large investment from the Member States and takes years. Classification and labeling is essential in the communication of the hazardous properties of substances and mixtures and is amongst others an important first step in the identification of a substance as a Substance of Very High Concern (SVHC). REACH will hardly generate sufficient information for classification of substances as category 1B for mutagenicity and carcinogenicity. Therefore, indications of very severe hazards of substances are missed and health risks could occur. There are various ways to deal with this problem, however as most of these require adaptation of regulations this will cost considerable time and political will. This study is a first step to raise awareness for the problem and to start a discussion to search for a sustainable solution.
Introduction REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) (REACH regulation (EC) No 1907 /2006 ) aims to ensure a high level of protection of human health and the environment, including the promotion of alternative methods for assessment of hazards of substances, as well as the free circulation of substances on the internal market while enhancing competitiveness and innovation. One of the key elements in REACH is that industry is responsible for proving the safe use of their substances, instead of authorities. Therefore, REACH obliges companies to register and test all substances produced or imported in the EU in quantities greater than 1 ton per year. Annexes VII to X of the REACH Regulation contain the standard information requirements for the different tonnage bands; Annex XI describes the rules for adaptation of the standard testing regime.
The CLP (Classification, Labelling and Packaging) Regulation (CLP regulation (EC) No 1272/2008) ensures that the hazards presented by chemicals are clearly communicated to workers and consumers through classification and labeling of chemicals. Classification and labeling is an important indicator for downstream users to alert them on the presence of dangerous chemicals in their products. Exposure and/or risk assessment is not part of classification and labeling process, these assessments can be a good next step in evaluating the use and use conditions of the substance.
Before placing chemicals on the market, industry must establish the potential risks (hazards) to human health and the environment of the substances on their own or in mixtures, classifying them accordingly. CLP sets standard criteria that should be used to determine the hazardous properties of a substance and the appropriate classification.
Substances fulfilling certain hazard criteria or which are proposed as active substances within plant protection products and biocides shall normally be evaluated under harmonized classification (CLH) on EU level. This includes amongst others the evaluation of the carcinogenicity, mutagenicity, and reproductive toxicity.
To achieve a harmonized classification, a CLH-report with the classification proposal has to be drafted by an EU Member State or a manufacturer, importer, or downstream user. The report shall contain sufficient information on the physical, toxicological, or ecotoxicological hazardous property(ies) to allow an independent assessment of the classification proposal by the Committee for Risk Assessment (RAC) of the European Chemicals Agency (ECHA). The scientific opinion on the proposal as issued by RAC is forwarded to the European Commission who, in cooperation with the Member State competent authorities and the European Parliament, adapts the legislation to include the harmonized classification in Annex VI of the CLP regulation.
The information used to draft a CLH-report usually consists primarily of studies available in the REACH registration dossier of the substance. Thus, the REACH data requirements for the substance's respective tonnage directly influence whether a substance can fulfill the criteria for classification.
Harmonized classification in turn is, amongst others, an essential step in the regulation of substances under REACH and the identification of Substances of Very High Concern (SVHC) (see ECHA 2013 for further details on SVHC substances).
A signal voiced at the start of REACH was that for many, in particular low tonnage, substances, no or few higher-tier toxicity studies are required. This led to the concern that the REACH information requirements will not always provide sufficient information to determine the classification of substances (Rud en & Hansson 2010) . Based on experience of the first 10 years under REACH, there are indications that this concern is indeed justified, in particular for the endpoints mutagenicity and carcinogenicity. For example, an evaluation by the Joint Research Center (JRC) found that for 0.0% of substances registered under REACH a carcinogenicity study had been performed up to 2014 (Madia et al. 2016) .
Classification Criteria for Mutagenicity
Category 1A is based on positive evidence from human epidemiological studies Category 1B is based on: -positive result(s) from in vivo heritable germ cell mutagenicity tests in mammals; or -positive result(s) from in vivo somatic cell mutagenicity tests in mammals, in combination with some evidence that the substance has potential to cause mutations to germ cells. It is possible to derive this supporting evidence from mutagenicity/genotoxicity tests in germ cells in vivo, or by demonstrating the ability of the substance or its metabolite(s) to interact with the genetic material of germ cells; or -positive results from tests showing mutagenic effects in the germ cells of humans, without demonstration of transmission to progeny; for example, an increase in the frequency of aneuploidy in sperm cells of exposed people.
Category 2 is based on positive evidence obtained from experiments in mammals and/or in some cases from in vitro experiments, obtained from:
-somatic cell mutagenicity tests in vivo, in mammals; or -other in vivo somatic cell genotoxicity tests which are supported by positive results from in vitro mutagenicity assays Note: Substances which are positive in in vitro mammalian mutagenicity assays, and which also show chemical structure activity relationship to known germ cell mutagens, shall be considered for classification as Category 2 mutagens.
Source: (CLP regulation (EC) No 1272/2008
In this paper, the REACH data requirements and studies obtained in the substance evaluation (SEv) for these endpoints are compared with the CLH criteria for classification and the conclusions of RAC opinions on CLH proposals. This will be followed by a discussion on the downstream consequences and potential future developments.
Comparison of the reach data requirements and classification under CLP: Germ cell mutagenicity

Classification for germ cell mutagenicity
A substance is classified for germ cell mutagenicity if it has the ability to induce heritable mutations in the germ cells of humans. The category of classification depends on the weight of evidence, see Classification Criteria for Mutagenicity. There is no separate classification for mutagenicity in somatic cells, as mutations in somatic cells are not inheritable.
In addition to the classification criteria as stated in the CLP Regulation, also the interpretation of these criteria should be considered. To this end, the RAC opinions of all substances classified for germ cell mutagenicity since the entry into force of the CLP Regulation (2009) until July 2017 have been reviewed 1 to determine which study(ies) has(ve) been critical to conclude that the substance should be classified as such. The substances investigated are presented in Table A1 of the Appendix.
In the period 2009-2017, five substances were classified as Category 1B (Cat 1B) mutagens and 11 as Category 2 (Cat 2) mutagens. Of the five Cat 1B substances, four were classified because they contain or form a substance with an existing classification as Cat 1B mutagen.
Only one substance, geranonitrile (3,7-dimethylocta-2,6-dienenitrile), was classified in Cat 1B solely on studies that were performed with the substance itself. The critical studies in this case were a positive in vivo mouse spermatogonial cell chromosome aberration assay (OECD 483) in combination with three positive mouse bone marrow micronucleus tests (OECD 474), and a toxicokinetic study using radiolabeling and showing exposure of the gonads (OECD 417). Two of the criteria for Cat 1B were therefore met.
For the substances classified in Cat 2, the critical studies were usually in vivo mutagenicity assays in somatic cells, either at the site of contact and/or in the bone marrow, with in vitro studies as supportive evidence. In these cases, germ cell mutagenicity studies were either negative (formaldehyde, di-tert-butylperoxide), lacking in quality (acetaldehyde, 2,3-epoxypropyl methacrylate), using a non-physiological route of exposure (tert-butyl hydroperoxide), or absent (dibutyltin dilaurate, pyrocatechol, leucomalachite green). Three substances were classified based on read-across because they are hydrolyzed into formaldehyde.
Toxicokinetic studies that could provide information regarding the exposure of the germ cells were often absent or flawed. Even if there was toxicokinetic evidence to prove a substance is systemically available (in fact all positive oral in vivo tests in bone marrow or other organs in principle already demonstrate the substance is systemically available), this was not sufficient for classification in Cat 1B, for which evidence of actual interaction with the genetic material of germ cells is required (see Classification Criteria for Mutagenicity). An example is dibutyltin dilaurate (DBTDL), for which there was a positive in vivo micronucleus test with its hydrolysis product dibutyltin dichloride (DBTC) (OECD 474), supported by a Comet assay (non-guideline) with DBTDL itself. Although it was indicated that DBTDL was systemically available, it was classified in Cat 2 amongst others because there was no information to prove direct interaction with the germ cells. In the RAC opinion it was stated that: "Although distribution into testes/ovaries can be expected, no experimental evidence is available which demonstrates a direct interaction of the substance or its metabolite with the genetic material of germ cells. Therefore, RAC considers classification in category 1B not appropriate."
Considering the RAC opinions it can be concluded that, so far, a positive germ cell mutagenicity test appeared to be essential for classification in Cat 1B. Although 1 When reviewing the RAC opinions, only the opinions positively concluding on a carcinogen and/or mutagen classification were included. Although these opinions give a good indication of the data required to reach a classification, it would also be very useful to know for which substances RAC did not conclude on a classification due to a lack of data. Unfortunately, it was not feasible to include these opinions, as they cannot be readily found without going through each opinion manually.
classification may also be possible if there is toxicokinetic evidence that proves direct interaction with the germ cells, this has not yet occurred and systemic availability in itself is apparently not considered sufficient evidence. For classification in Cat 2, at least one somatic in vivo mutagenicity study is required. Alternatively, substances have been, and thus can be, classified if they hydrolyze or metabolize into a previously classified mutagen.
The REACH data requirements for mutagenicity According to the REACH information requirements, the only compulsory studies are in vitro studies; in bacteria for substances at any tonnage level (Annex VII-X) and in mammalian cells for substances produced or imported in !10 t/y (Annex VIII-X). In case of a positive in vitro genotoxicity test, a somatic in vivo test shall be considered for substances in Annex VII and VIII and becomes compulsory for Annex IX and X substances (! 100 t/y). When the somatic cell assay is positive, additional investigations (e.g., a germ cell test) shall be considered by the registrant (see Table 1 ). However, the word "considered" means there is no strict legal requirement to perform the germ cell assay. There is also no obligation to report whether a germ cell assay was considered or why it is not proposed. It is further to be noted that toxicokinetic studies that could be used to determine whether a substance can reach the germ cells and DNA adduct measurements to determine the interaction with germ cells are not standard requirement under REACH at any tonnage level.
Comparison between REACH and CLP
When comparing the REACH information requirements with the information required to meet the classification criteria for mutagenicity, it can be concluded that:
for Cat 2, the somatic in vivo study necessary for classification will normally only be available for Annex IX and X substances (! 100 t/y), which are positive in in vitro assays. for Cat 1B, sufficient information will normally not be available for any substance.
Registrants shall consider performing a germ cell test when the somatic cell test is positive and there is no evidence to prove that the substance will not reach the germ cells. However, the germ cell mutagenicity test is expensive and time consuming and, importantly, classification in Cat 1B has severe downstream consequences. In the absence of a legal obligation for registrants, these considerations form very strong incentives not to carry out a germ cell test. For low tonnage substances that are positive in in vitro assays, it is also not compulsory to perform additional testing. This is left to the registrant for consideration.
An alternative way of getting information on the in vivo potential of a substance for somatic and/or germ cell mutagenicity is via the SEv process under REACH. In this process, a Member State can ask for an in vivo test if they have a concern for potential mutagenicity of a substance. The SEv process is time-consuming and requires Figure 1 ). The Member State has to select (potentially) mutagenic substances, substantiate the exact reason for concern in a SEv report and formulate the request for testing in a draft decision document. This document has to be discussed and approved in ECHA's Member State Committee (MSC), after which the decision is sent to the registrant who subsequently has to conduct the test(s) and update the registration dossier. As a result, the whole process from substance selection until the inclusion of the new study in the registration dossier takes about 5-7 years and even longer when the registrant appeals against the decision. The subsequent classification process takes another 2-4 years, which brings the total time required from initial concern to classification to approximately 7-11 years. Another issue in the SEv process is that the Member State has to substantiate its concern. For a germ cell mutagenicity test the justification of the concern always included at least one positive in vivo somatic cell mutagenicity study. If only in vitro assays are available, which is often the case for Annex VII and VIII substances, it might be more problematic to substantiate the concern in order to request direct germ cell testing.
To our knowledge, only three SEv requests for a germ cell mutagenicity study (OECD 488 Two additional SEv's with requests for germ cell mutagenicity studies (OECD 488) were discussed and approved in the MSC meeting of December 2017 (4,4'methylenebis[N,N-bis (2,3-epoxypropyl)}aniline and 2,3-epoxypropyl o-tolyl ether), but these are still in the period in which the registrant can start an appeal. No germ cell genotoxicity testing (OECD 478, 483, or 488) has ever been requested by ECHA in a compliance check (CCH) or proposed on the registrant's initiative in a testing proposal (TPE).
The (few) germ cell tests used in the harmonized classification process were performed under the previous chemical legislation, before the REACH regulation was implemented. For example, the in vivo germ cells test used for the classification of geranonitrile was performed in 2006 (RCC-CCR (2006)). Also the available germ cell tests with formaldehyde (9 studies, 1968-2009) and acetaldehyde (2 studies, 1988 and 2002) were performed before the implementation of REACH.
In conclusion, the REACH standard data requirements will normally not provide the studies necessary to classify a substance as a Cat 1B mutagen, at any tonnage level; Cat 2 is the maximum achievable. Although it is possible to request additional studies in a SEv, this requires a large investment from Member States and takes years. Moreover, information to trigger such an assessment is not readily available. As a result, an SEv to request a (germ cell) mutagenicity study will be performed only in a limited number of cases.
Comparison of the reach data requirements and classification under CLP: Carcinogenicity
Classification for carcinogenicity
Substances are classified as carcinogens if they can induce cancer or increase its incidence, see Classification Criteria for Carcinogenicity. The classification can be limited to a certain route of exposure if it can be conclusively proved that no other route exhibits the hazard. The category of the classification reflects the strength of evidence, with a differentiation between sufficient evidence (Category 1B) and limited evidence (Category 2).
The distinction between sufficient and limited is further defined in the CLP Regulation (Section 3.6.2.2), but refers mainly to the strength of the causality between exposure to the substance and the onset of cancer. For animal experiments, repeatability is also an important factor. If there is only one study available, this is by default defined as limited evidence, leading to Cat 2, unless it is very reliable and the outcome is exceptionally strong (high tumor incidence and/or both sexes). If there are multiple positive studies, preferably in two species, this is by default considered sufficient evidence (Cat 1B), unless there are serious doubts on the reliability of these studies or the relevance of the observed tumors for humans.
As there are many factors that influence the reliability of studies and the strength of causality, a thorough weighing of all available data by experts is essential to reach conclusions on the classification for carcinogenicity. To determine what evidence is usually necessary, a review was performed of all published RAC opinions of industrial chemicals in which a classification for carcinogenicity was proposed in the period of 2009-2017 (see Table A2 of the Appendix, and footnote on p.2). Plant protection products and biocides have been excluded, as these substances have different data requirements than industrial chemicals. A total of 25 RAC opinions were included, one advising Cat 1A, eleven Cat 1B, and thirteen Cat 2 for carcinogenicity.
Classification Criteria for Carcinogenicity
Category 1A (known human carcinogen) is largely based on human evidence that establishes a causal relationship between human exposure to a substance and the development of cancer.
Category 1B (presumed human carcinogen) is usually based on animal experiments for which there is sufficient evidence to demonstrate animal carcinogenicity.
In addition, on a case-by-case basis, scientific judgement may warrant a decision of Cat 1B derived from studies showing limited evidence of carcinogenicity in humans together with limited evidence of carcinogenicity in experimental animals.
Category 2 (suspected human carcinogen) is based on evidence obtained from human and/or animal studies, which is not sufficiently convincing to place the substance in Category 1A or 1B, based on strength of evidence together with additional considerations. Such evidence may be derived either from limited evidence of carcinogenicity in human studies or from limited evidence of carcinogenicity in animal studies.
Source: (CLP regulation (EC) No 1272/2008)
The Cat 1A substance was coal tar pitch, high temperature, for which there was a large body of evidence in both humans and animals that showed both the substance itself and some of its constituents (mainly polycyclic hydrocarbons, PAHs) to be carcinogenic.
Of the Cat 1B carcinogens, three were classified mainly on the basis of read-across to a related substance or breakdown product with an existing cat 1B classification for carcinogenicity that predated REACH (cadmium carbonate, hydroxide, and nitrate; 2,3-epoxypropyl methacrylate; gallium arsenide). For the other eight substances, there were always at least two positive carcinogenicity studies available, and in all cases except one (e-glass microfibers) these were performed in at least two different species (acetaldehyde, anthraquinone, 1,2-dichloropropane, 1,2-dihydroxybenzene, E-glass microfibers of representative composition, indium phosphide, formaldehyde, methylhydrazine). All studies were conducted before REACH came into force.
Two of the Cat 2 carcinogens, PFOA and PFNA (Perfluorooctanoic acid and Per-fluorononanoic acid), were classified on the basis of read-across to their structural analogue APFO (Ammoniumpentadeca-fluorooctanoate). For 10 substances, there were multiple studies available, often in both rats and mice, but either one species did not show an increase in tumor incidence or there were doubts on the reliability of the studies or the relevance of the tumors for humans. There was only one substance, tris(1,3-Dichloro-2-Propyl)Phosphate (TDCP), for which there was only one study available. Although this study was clearly positive, TDCP was not classified in Cat 1B but in Cat 2 because the mode of action was unknown and the substance was negative in in vivo and in vitro mutagenicity studies.
In addition to the category, also the exposure route is of importance for carcinogenicity classification. Of the reported substances, eight were mainly or only classified based on inhalation studies, while for two substances the evidence consisted of a mixture of oral and inhalation studies. If only oral studies would have been available for these substances (the default under REACH), they would not have been classified.
The REACH data requirements for carcinogenicity
Under REACH, a carcinogenicity study may be proposed by the registrant or required by ECHA for Annex X substances that are produced or imported in more than 1000 t/ y, and only if the substance has wide dispersive use or there is evidence of frequent or long-term exposure and the substance is classified as germ cell mutagen Cat 2 or there is evidence from the repeated dose study (ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions ( Table 2 ). If the substance is classified as Cat 1A/B mutagen, it is considered likely to be carcinogenic by a mutagenic mode of action and no carcinogenicity study is required.
This means that no carcinogenicity study will be performed for a substance that is produced or imported in <1000 t/y; has no wide dispersive use/evidence of frequent or long-term exposure; is not classified for mutagenicity Cat 2 or induces no hyperplasia/pre-neoplastic lesions in repeated dose studies (for example non-genotoxic carcinogens); is a Cat 1A/B mutagen 2 2. No carcinogenicity testing has to be performed for a Cat 1B mutagen, because it is assumed that the substance will be carcinogenic as well. This has the following disadvantages:
However, even for substances that fulfill all the requirements, a carcinogenicity study only has to be performed when ECHA specifically requires it, which means the data gap has to be identified in a compliance check of the registration dossier. Note that this is different for mutagenicity, where testing cannot be required in a compliance check. The experience with compliance checks so far learns that this rarely, if at all, results in a request for a carcinogenicity study. Recently though such a case was discussed in the MSC (sodium hydroxymethanesulphinate, at time of writing in the 3 month appeal period) and in 2012 there was the case of tert-butyl peroxide (study ongoing).
It is also possible for a Member State to request a carcinogenicity study via a SEv. However, in the first 10 years of REACH there has not been a single SEv decision on the conduct of a carcinogenicity study, which could either mean that it is difficult to request such a study or all Annex X substances do not have this potential, or these substances do not have a wide dispersive use
Comparison between REACH and CLP
Obviously, if there is no carcinogenicity study available and no possibility to use readacross, the carcinogenic properties of a substance cannot be evaluated under CLP. It is to be noted that whether a single carcinogenicity study provides sufficient information to determine the correct classification is much harder to determine. According to the CLP regulation, it is possible to classify a substance as Cat 1B carcinogen on the basis of one positive study, provided the study is reliable, the substance affects multiple organs, and the outcome is unequivocal. However, in the review of the RAC opinions none of the Cat 1B substances was classified on one study.
One substance (TDCP) was classified in Cat 2 on only one study. For all other substances, there were always at least two studies available (although not always multiple positive studies in case of Cat 2).
Again as noted before, none of the studies evaluated by RAC were conducted after REACH came into force.
The general impression from the RAC opinions is that substances with two positive carcinogenicity studies are classified in Cat 1B, and substances with one positive study or multiple positive studies with limitations are classified in Cat 2. Given the fact that for substances without already existing carcinogenicity data the REACH data requirement will not likely provide any carcinogenicity study, or if at all, only one at a time, there will be no or insufficient evidence to assess the carcinogenicity of a substance, and thus the proper classification. At most, Cat 2 will be possible, but only in very rare cases and Cat 1B seems impossible.
Conclusion
The comparison of the classification criteria and RAC opinions with the REACH data requirements shows that for the majority of substances, the standard information o The substance will not be labeled as carcinogenic. o There is no information on tumor type/incidence or dose-response curve, which is necessary for both risk assessment of the substance, for example after accidental exposure, and for the socio-economic impact analysis in, for example, the Authorisation process.
requirements under REACH are insufficient to conclude whether a substance should be considered as a Cat 1B mutagen and/or carcinogen. The germ cell mutagenicity test that seems to be required for Cat 1B Muta is not compulsory; it can only be requested in a SEv. Also carcinogenicity testing is only required conditionally, for a very small number of high volume substances. Moreover, the system only allows in rare cases to ask for one carcinogenicity study at a time and not for two, as appears to be essential to conclude on classification in category 1B.
Why is classification for mutagenicity and carcinogenicity important?
The classification of a substance as mutagenic or carcinogenic (CM) has severe implications for the permitted use of the substance and the safety requirements that have to be taken when handling the substance. This is particularly true for substances with a Cat 1A/1B classification.
A failure to classify a substance as CM due to a lack of data and in particular CM Cat 1A/1B has severe consequences for the safety of both workers and consumers. Without classification, users will not be warned for the hazard these substances pose and they can be used in products that may lead to high levels of exposure. In the long term, this may lead to substance related cancers or inheritable mutations.
When a substance is classified as CM, it has to be labeled with the serious health hazard symbol, as well as mixtures containing the substance at 0.1% (Cat 1A/1B) or 1% (Cat 2).
As stated in REACH Annex XVII, entries 28 and 29, harmonized CM Cat 1A/B substances may not be placed on the market to be used by the general public, either as a pure substance or as constituent or in a mixture. A generic concentration limit of 0.1% applies to the use in mixtures, although there are specific concentration limits for some substances.
According to REACH Art 57 a and b, CM Cat 1A/1B substances may be included in the candidate list of SVHC. Substances on this list that can be prioritized for inclusion in the Authorization list of REACH (Annex XIV), which means an authorization should be applied for in order to use the substance in articles. CM substances are often selected with priority by Member States for inclusion on the candidate list of SVHC substances.
The worker legislation (Directive 2004/37/EC) also has specific provisions for Cat 1A/ 1B mutagens and carcinogens. Employers should reduce the use of CM substances by replacement with safer alternatives whenever possible. In cases where replacement is not possible, exposure of workers should be prevented, by measures such as use of closed systems, ventilation measures, and/or personal protective equipment.
Harmonized Classification in Cat 2 has much less severe consequences, although also these substances/mixtures have to be labeled. There are legislations for specific products or articles that regulate or restrict the use of CM Cat 2 substances, such as the toys directive (DIRECTIVE 2009/48/EC) and the cosmetics regulation (REGULATION (EC) No 1223/2009).
A classification in Cat 2 can also be a trigger to request additional studies, in particular Muta Cat 2, which is a trigger for a carcinogenicity study. These new studies may lead to a higher classification, depending on their outcome.
Some initial thoughts on future developments and possible solutions
The REACH legislation was born out of a desire to gain more knowledge about existing chemicals, to create a level playing field for new and existing substances, and to give industry the responsibility for the safety of their substances (Foth & Hayes, 2008; Spencer et al. 2009 ).
The link between data requirements and tonnage per year is designed to gain insight in the hazardous properties of substances, while being proportional to their use. However, as demonstrated by comparing the required studies with the CLP Regulation and RAC opinions, the REACH standard requirements will normally not provide sufficient information to conclude whether a substance with indications for mutagenicity or carcinogenicity is a Cat 1B mutagen or carcinogen, not even at the highest tonnage level. Alternatively, the required studies can be requested by a Member State in a SEv procedure, but this is very time consuming and requires awareness and substantiation of the data gap, which means at least some information has to be available. Not being able to conclude on Cat 1B for endpoints like mutagenicity and carcinogenicity has an impact on the risk management options and as such could have a serious impact on human safety.
This study was started to raise awareness on this issue. Although we realize there is no easy solution, some thoughts will be given to ways to address this problem.
There are three routes that may solve or at least reduce the problem:
Adaptation of the REACH information requirements Adaptation of the CLP criteria Lowering of the SVHC criteria and other criteria for downstream consequences
Adaptation of the REACH information requirements
Concerning the REACH information requirements, the main cause of the lack of in vivo mutagenicity and carcinogenicity studies is that their execution is bound to conditions. Moreover, even when these conditions are met, the germ cell mutagenicity test (required for Muta Cat 1B) and the carcinogenicity study (required for Carc Cat 1B and 2) are not automatically required.
The obvious solution would be to at least make these studies compulsory if the conditions are met, which can be implemented by changing "shall be considered" in the REACH regulation into "shall be proposed" (REACH Annex IX, 8.4 Column 2, germ cell mutagenicity, last sentence) and "may be proposed" into "shall be proposed" (REACH Annex X, 8.9.1 Column 2, carcinogenicity, first sentence). The resulting formulation of the REACH information requirements are given in Table 3 .
To avoid missing non-mutagenic carcinogens and mutagens that are negative in vitro amongst others, one could also move the in vivo somatic and germ cell mutagenicity studies and the carcinogenicity study to Column I of REACH Annexes IX and X and remove the conditions altogether. This would make them standard requirements, akin to the Pre-natal Development Toxicity studies (PNDT) and Extended One-generation Toxicity study (EOGRT) required for reproductive toxicity testing. However, as most substances that are negative in vitro are also negative in vivo, it is questionable whether the number of additional mutagens/carcinogens identified is proportional to the costs of the tests.
There are various forces that oppose a change of the data requirements; otherwise these conditions would not have been included in the first place. The germ cell mutagenicity study and in particular a carcinogenicity study are animal, time, and money consuming. The consequence of a CM Cat 1A/1B classification is that safety measures have to be implemented to protect those working with or using these substances and the products/articles containing them. However, these measures also limit the usability of these substances, which could be an incentive for registrants not to further investigate the mutagenicity if this is not compulsory. Another aspect that clashes with the extension of the data requirements is the desire to reduce animal testing. The tests required for a CM classification are all in vivo tests, usually performed on mice and/or rats. The only alternative method that is accepted so far for the classification of substances as CM is read-across to a closely related substance or metabolite. While read-across can limit the number of studies that have to be performed, it cannot replace them entirely since there still need to be studies available on the closely related substance or metabolite.
Adaptation of the CLP criteria
The second option to address both the lack of data and reduce the number of animal studies is to change the CLP criteria for classification. For example, by including positive in vitro evidence as criterion for a Cat 2 mutagen, without requiring an additional in vivo study or read-across to a related substance, and/or to accept a somatic mutagenicity study for Cat 1B if there are no data to prove the substance will not reach the gonads/germ cells. As the CLP criteria are based on the GHS criteria (the global harmonized system for classification, http://www.unece.org/trans/danger/publi/ghs/ghs_ welcome_e.html), any change requires global consensus of countries, which is a long, difficult and uncertain process.
The assessment of carcinogenicity will still require a carcinogenicity study, at least in the foreseeable future, and the CLP criteria already leave room to classify a substance on a single study, but only those substances that affect multiple organs can potentially be classified as Cat 1B. However, if it becomes possible to classify substances as Cat 2 mutagens on in vitro evidence, this will indirectly also lower the barrier to request carcinogenicity studies.
Lowering of the SVHC criteria and other criteria for downstream consequences
A third option within REACH is to change the SVHC criteria in REACH Art 57 a and b to also include Cat 2 CM substances. This would mean that similar measures would apply for Cat 2 substances as for Cat 1A/1B substances. Comparable changes on management options could be considered for other legislations that depend on the classification for carcinogenicity and mutagenicity, such as worker legislation and the regulations of for example pesticides and cosmetics.
Conclusion
After 10 years of REACH it is noted that the standard information requirements under REACH often do not provide sufficient information to conclude on Muta 1A/1B/Carc 1A/1B. The SEv process is very long and requires a large investment of the member states and as a result hardly ever provides the information needed to conclude on these endpoints. Since harmonized classification for CM is an essential step for several risk management options, including the identification of a substance as SVHC (under Art 57 a and b) with its ultimate inclusion into Annex XIV, the consequence could be that potential risk for workers and consumers exposed to these substances might be overlooked. There are several options that can be considered to reduce or eliminate this problem. As most of these require the adaptation of regulations, this will cost considerable time and political will. Nevertheless, the intention of our study is to raise awareness on the tension between the information obtained under REACH and the information needed to regulate for mutagenicity and carcinogenicity and to start a discussion on this topic. 
Category of the classification
Critical studies Link to RAC opinion no tumours after inhalation in mice 4-Vinylcyclohexene Cat. 2, H351 A carc study in mice showed ovary tumors, also a rat carc study was positive, but had low reliability due to overt mortality http://echa.europa.eu/documents/10162/21259a45-ea7e-4c23-bd92-911018ff21ec
